<ins id="whowg"><noframes id="whowg"></noframes></ins>

Splitomicin NEW

Price	$57	$117	$182
Package	10mg	25mg	50mg

Min. Order:
Supply Ability:	10g
Update Time:	2025-07-21

Product Details

Product Name: Splitomicin	CAS No.: 5690-03-9
Purity: 98.64%	Supply Ability: 10g
Release date: 2025/07/21

Product Introduction

Bioactivity

Name	Splitomicin
Description	Splitomicin (1-Naphthalenepropanoic Acid) (IC50 of 60 μM), a specific inhibitor of NAD(+)-dependent histone deacetylase Sir2p, displays a high activity in a cell-based assay.
In vitro	Splitomicin inhibits Sir2p deacetylase activity by altering or blocking access to the acetylated histone binding pocket. [1] Splitomicin inhibits platelet aggregation induced by thrombin, collagen, AA and U46619 via inhibition of cyclic AMP phosphodiesterase activity and subsequent inhibition of intracellular Ca(++) mobilization, TXB2 formation and ATP release. [2]
In vivo	In a photochemical injury mouse model, splitomicin (80 mg/kg/d i.p.) enhances tissue factor activity in the arterial vessel wall and promotes carotid artery thrombus formation. [3]
Storage	Powder: -20°C for 3 years \| In solvent: -80°C for 1 year \| Shipping with blue ice/Shipping at ambient temperature.
Solubility Information	DMSO : 19.8 mg/mL (99.89 mM), Sonication is recommended. Ethanol : 19.8 mg/mL (99.89 mM), Sonication is recommended.
Keywords	Splitomycin \| Splitomicin \| SIRT2p \| Inhibitor \| inhibit \| Histone deacetylases \| HDAC
Inhibitors Related	Valproic acid sodium salt \| Panobinostat \| Theophylline monohydrate \| Sodium 4-phenylbutyrate \| Acefylline \| Dihydrocoumarin \| Resveratrol \| Valproic Acid \| Curcumin \| Fisetin \| 4-Phenylbutyric acid \| Nicotinamide
Related Compound Libraries	Histone Modification Compound Library \| HIF-1 Signaling Pathway Compound Library \| Chromatin Modification Compound Library \| Inhibitor Library \| Stem Cell Differentiation Compound Library \| NO PAINS Compound Library \| Anti-Aging Compound Library \| Anti-Cancer Compound Library \| Human Metabolite Library

Company Profile Introduction

Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers. TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.